RT Journal Article
SR Electronic
T1 Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 153
OP 157
DO 10.1136/ijgc-2018-000034
VO 29
IS 1
A1 Elisa Tripodi
A1 Gennaro Cormio
A1 Ugo De Giorgi
A1 Giorgio Valabrega
A1 Daniela Rubino
A1 Stefano Lepori
A1 Giuseppa Maltese
A1 Ilaria Sabatucci
A1 Domenica Lorusso
YR 2019
UL http://ijgc.bmj.com/content/29/1/153.abstract
AB Background Pegylated liposomal doxorubicin (PLD) is an active and well-tolerable treatment in ovarian cancer relapse, either alone or in combination with other drugs. No data are available on the possibility to rechallenge PLD treatment in long survivor patients with recurrent ovarian cancer, as evaluated for platinum agent, paclitaxel and gemcitabine. The aim of the present study was to evaluate the anti-tumor activity and the toxicity profile of re-challenge of PLD in recurrent ovarian cancer patients.Methods Data on 27 patients with epithelial ovarian cancer treated in the last ten years (2007-2017) with palliative PLD rechallenge were included in this multicenter retrospective Italian study.Results The objective response rate to PLD re-treatment were complete response in 19%, partial response in 30% and stable disease in 37%. Only 1 case of G4 hematological toxicity was reported. No patient experienced severe cardiac impairment (G2-4).Conclusion PLD rechallenge represents an active and safe possibility of treatment for long survivor ovarian cancer patients.